These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 16374456)

  • 41. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants.
    Puntervoll HE; Yang XR; Vetti HH; Bachmann IM; Avril MF; Benfodda M; Catricalà C; Dalle S; Duval-Modeste AB; Ghiorzo P; Grammatico P; Harland M; Hayward NK; Hu HH; Jouary T; Martin-Denavit T; Ozola A; Palmer JM; Pastorino L; Pjanova D; Soufir N; Steine SJ; Stratigos AJ; Thomas L; Tinat J; Tsao H; Veinalde R; Tucker MA; Bressac-de Paillerets B; Newton-Bishop JA; Goldstein AM; Akslen LA; Molven A
    J Med Genet; 2013 Apr; 50(4):264-70. PubMed ID: 23384855
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.
    Aoude LG; Gartside M; Johansson P; Palmer JM; Symmons J; Martin NG; Montgomery GW; Hayward NK
    Twin Res Hum Genet; 2015 Apr; 18(2):126-33. PubMed ID: 25787093
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.
    Goldstein AM; Chan M; Harland M; Hayward NK; Demenais F; Bishop DT; Azizi E; Bergman W; Bianchi-Scarra G; Bruno W; Calista D; Albright LA; Chaudru V; Chompret A; Cuellar F; Elder DE; Ghiorzo P; Gillanders EM; Gruis NA; Hansson J; Hogg D; Holland EA; Kanetsky PA; Kefford RF; Landi MT; Lang J; Leachman SA; MacKie RM; Magnusson V; Mann GJ; Bishop JN; Palmer JM; Puig S; Puig-Butille JA; Stark M; Tsao H; Tucker MA; Whitaker L; Yakobson E; ;
    J Med Genet; 2007 Feb; 44(2):99-106. PubMed ID: 16905682
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein.
    Sun S; Pollock PM; Liu L; Karimi S; Jothy S; Milner BJ; Renwick A; Lassam NJ; Hayward NK; Hogg D; Narod SA; Foulkes WD
    Int J Cancer; 1997 Nov; 73(4):531-6. PubMed ID: 9389568
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes.
    Soufir N; Bressac-de Paillerets B; Desjardins L; Lévy C; Bombled J; Gorin I; Schlienger P; Stoppa-Lyonnet D
    Br J Cancer; 2000 Feb; 82(4):818-22. PubMed ID: 10732752
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Germline CDKN2A mutations in childhood melanoma: a case of melanoma-pancreatic cancer syndrome.
    Gironi LC; Colombo E; Farinelli P; Giorgione R; Bozzola C; Ogliara P; Pasini B
    Int J Dermatol; 2015 Dec; 54(12):e553-5. PubMed ID: 26381259
    [No Abstract]   [Full Text] [Related]  

  • 47. Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients.
    Mantelli M; Pastorino L; Ghiorzo P; Barile M; Bruno W; Gargiulo S; Sormani MP; Gliori S; Vecchio S; Ciotti P; Sertoli MR; Queirolo P; Goldstein AM; Bianchi-Scarrà G;
    Melanoma Res; 2004 Dec; 14(6):443-8. PubMed ID: 15577313
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.
    Helgadottir H; Tuominen R; Olsson H; Hansson J; Höiom V
    J Am Acad Dermatol; 2017 Nov; 77(5):893-901. PubMed ID: 28818438
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [From gene to disease; from p16 to melanoma].
    Gruis NA; Bergman W
    Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families.
    Peric B; Cerkovnik P; Novakovic S; Zgajnar J; Besic N; Hocevar M
    BMC Med Genet; 2008 Sep; 9():86. PubMed ID: 18803811
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
    McWilliams RR; Wieben ED; Rabe KG; Pedersen KS; Wu Y; Sicotte H; Petersen GM
    Eur J Hum Genet; 2011 Apr; 19(4):472-8. PubMed ID: 21150883
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer.
    Nagore E; Montoro A; García-Casado Z; Botella-Estrada R; Insa A; Lluch A; López-Guerrero JA; Guillén C
    Melanoma Res; 2009 Aug; 19(4):211-4. PubMed ID: 19571771
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel and recurrent p14 mutations in Italian familial melanoma.
    Binni F; Antigoni I; De Simone P; Majore S; Silipo V; Crisi A; Amantea A; Pacchiarini D; Castori M; De Bernardo C; Catricalà C; Grammatico P
    Clin Genet; 2010 Jun; 77(6):581-6. PubMed ID: 20132244
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.
    Nielsen K; Harbst K; Måsbäck A; Jönsson G; Borg A; Olsson H; Ingvar C
    Melanoma Res; 2010 Aug; 20(4):266-72. PubMed ID: 20526219
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanoma-prone kindreds.
    Lang JM; Shennan M; Njauw JC; Luo S; Bishop JN; Harland M; Hayward NK; Tucker MA; Goldstein AM; Landi MT; Puig S; Gruis NA; Bergman W; Bianchi-Scarra G; Ghiorzo P; Hogg D; Tsao H
    J Invest Dermatol; 2011 Feb; 131(2):480-6. PubMed ID: 21085193
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CDKN2A and MC1R mutations in patients with sporadic multiple primary melanoma.
    Peris K; Fargnoli MC; Pacifico A; Surrenti T; Stolz W; Wolf P; Soyer HP; Chimenti S
    J Invest Dermatol; 2004 May; 122(5):1327-30. PubMed ID: 15140239
    [No Abstract]   [Full Text] [Related]  

  • 57. Association of CDK4 germline and BRAF somatic mutations in a patient with multiple primary melanomas and BRAF inhibitor resistance.
    Governa M; Caprarella E; Dalla Pozza E; Vigato E; Maritan M; Caputo GG; Zannoni M; Rosina P; Elefanti L; Stagni C; Menin C
    Melanoma Res; 2015 Oct; 25(5):443-6. PubMed ID: 26110554
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 3'UTR-CDKN2A and CDK4 Germline Variants Are Associated With Susceptibility to Cutaneous Melanoma.
    Tovar-Parra D; Gil-Quiñones SR; Nova J; Gutiérrez-Castañeda LD
    In Vivo; 2021; 35(3):1529-1536. PubMed ID: 33910831
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical germline genetic testing for melanoma.
    Hansen CB; Wadge LM; Lowstuter K; Boucher K; Leachman SA
    Lancet Oncol; 2004 May; 5(5):314-9. PubMed ID: 15120668
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Germline mutation of ARF in a melanoma kindred.
    Hewitt C; Lee Wu C; Evans G; Howell A; Elles RG; Jordan R; Sloan P; Read AP; Thakker N
    Hum Mol Genet; 2002 May; 11(11):1273-9. PubMed ID: 12019208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.